Zdrowie i gospodarka · 26/10/2000

FDA Releases Revised Guidance on Submitting Complete Responses to Clinical Holds

The Food and Drug Administration (FDA) has published a revised guidance document outlining the process for submitting complete responses to clinical holds on investigational new drug (IND) applications, reflecting changes to the agency's clinical hold regulations and addressing commercial IND definitions and unresolved clinical trial issues.